Clinical Trials

39 enrolled

Lung Neoplasms

NCT05798845 2026-03-11

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

124 enrolled

NSCLC

NCT06775743 2026-03-11

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

53 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07017829 2026-03-11

GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

28 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07132918 2026-03-11

HEARTS Trial for Thoracic Cancers

60 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Thymoma

NCT07198841 2026-03-11

IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07463677 2026-03-11

Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer

55 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03523702 2026-03-10

SPRINT

Phase 2 Completed

25 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT05807048 2026-03-10

Daratumumab in STK11 Mutated NSCLC

Phase 2 Completed

8 enrolled

Non-small Cell Lung Cancer With STK11/LKB1 Mutation

NCT05044468 2026-03-09

EXPAREL or Lidocane as Local Anesthetic in Patients Undergoing Pleuroscopy With Pleural Biopsy and Indwelling Pleural Catheter Placement

80 enrolled

Malignant Pleural Neoplasm

NCT05669846 2026-03-09

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

26 enrolled

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT05986318 2026-03-09

RESPIRE-ILD

98 enrolled

Lung Neoplasms, Lung Diseases, Interstitial, Radiation Pneumonitis

NCT06951646 2026-03-09

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

70 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT07120282 2026-03-09

Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC

108 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01803542 2026-03-06

SBRT Lung

200 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04253964 2026-03-06

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

105 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

DermatologicGenitourinaryThoracic

35 enrolled

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

NCT05696782 2026-03-06

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

28 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06385262 2026-03-06

TOP 2301: Neoadjuvant Chemo for NSCLC

Phase 2 Suspended

126 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04516070 2026-03-05

Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis

55 enrolled

CNSThoracic

Brain Neoplasms, Lung Neoplasms, Small Cell Lung Carcinoma

NCT05672108 2026-03-05

Phase II Trial of Lung Chemoemobolization

GastrointestinalSarcomaThoracic

30 enrolled

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Mediastinal Neoplasms, Pleural Neoplasms, Sarcoma

NCT02675829 2026-03-04

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

131 enrolled

GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms, Urologic Neoplasms

NCT04716946 2026-03-04

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

13 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04880382 2026-03-04

OPTIMUNELUNG

Phase 2 Terminated

8 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05068232 2026-03-04

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

49 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06634056 2026-03-04

P4-PACIFIC

150 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06813664 2026-03-04

CURB-TKI

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07402343 2026-03-04

T-BRAIN

34 enrolled

CNSThoracic

Brain Neoplasms, Small Cell Lung Carcinoma

NCT07450183 2026-03-04

Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1

33 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06719700 2026-03-03

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

47 enrolled

Small Cell Lung Carcinoma

NCT07323732 2026-03-03

A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease

25 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Interstitial

NCT07447050 2026-03-03

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial

BreastGastrointestinalGynecologicHead & NeckSarcomaThoracic

24 enrolled

Breast Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms

NCT04318938 2026-03-02

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

118 enrolled

NSCLC

NCT04771520 2026-03-02

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

DermatologicGastrointestinalSarcomaThoracic

50 enrolled

Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

NCT03598309 2026-02-27

Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers

19 enrolled

Lung Diseases, Lung Neoplasms

NCT03808337 2026-02-27

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease